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In 2004, identiﬁ  cation of patients infected with the same 
Mycobacterium tuberculosis strain in New York, New York, 
USA, resulted in an outbreak investigation. The investigation 
involved data collection and analysis, establishing links 
between patients, and forming transmission hypotheses. 
Fifty-four geographically clustered cases were identiﬁ  ed 
during 2003–2009. Initially, the M. tuberculosis strain was 
drug susceptible. However, in 2006, isoniazid resistance 
emerged, resulting in isoniazid-resistant M. tuberculosis 
among 17 (31%) patients. Compared with patients with drug-
susceptible M. tuberculosis, a greater proportion of patients 
with isoniazid-resistant M. tuberculosis were US born and 
had a history of illegal drug use. No patients named one 
another as contacts. We used patient photographs to identify 
links between patients. Three links were associated with 
drug use among patients infected with isoniazid-resistant 
M. tuberculosis. The photographic method would have been 
more successful if used earlier in the investigation. Name-
based contact investigation might not identify all contacts, 
particularly when illegal drug use is involved.
N
ame-based contact investigation is a core tuberculosis 
(TB) control method, yet its limitations are documented 
(1–9). Although name-based contact investigations can 
elucidate TB transmission chains, these investigations are 
typically limited to household and other close contacts 
(10,11). Molecular characterization of Mycobacterium 
tuberculosis (i.e., TB genotyping), when combined 
with contact investigation, can increase screening yield 
and identify transmission venues, particularly among 
populations at high risk (e.g., substance users, immigrants, 
and other hard-to-reach populations) (2–5, 12,13).
Since 2001, the New York City (NYC) Bureau of 
Tuberculosis Control (BTBC), New York, New York, 
USA, has conducted universal genotyping and used results 
to detect and investigate clusters of TB with suspected 
recent transmission (14). One cluster, ﬁ  rst identiﬁ  ed and 
characterized in NYC in 2004, was the focus of an extensive 
epidemiologic investigation. We describe the investigation 
and discuss novel methods used during the investigation to 
understand TB transmission.
Materials and Methods
Since January 1, 2001, all initial culture-positive M. 
tuberculosis isolates have been characterized by using 
spacer oligonucleotide type analysis (spoligotyping) at the 
New York State Department of Health Wadsworth Center 
(Albany, NY, USA) and IS6110 restriction fragment 
length polymorphism (RFLP) typing at the Public Health 
Research Institute Tuberculosis Center (Newark, NJ, USA) 
(14). In accordance with Centers for Disease Control and 
Prevention (CDC) National Tuberculosis Genotyping 
Service, isolates were sent to the Michigan Bureau of 
Laboratories (Lansing, MI, USA) for 12-loci mycobacterial 
interspersed repetitive-unit variable-number tandem repeat 
(MIRU-VNTR) analysis (15).
Case Deﬁ  nition
Cluster membership was deﬁ  ned as patients who had 
a diagnosis of TB in NYC during 2003–2009 and whose 
isolates had identical spoligotype and IS6110 RFLP 
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patterns. As the investigation continued, this deﬁ  nition 
was expanded and included patients whose isolates had 
identical spoligotype, 12-loci MIRU-VNTR results, and 
IS6110 RFLP patterns with ± 1 band.
Drug Susceptibility Testing
TB drug susceptibility testing (DST) was performed 
at the NYC Public Health Laboratory and the Wadsworth 
Center on initial M. tuberculosis isolates by using either 
BACTEC 460 or Mycobacterial Growth Indicator Tube 
960 (Becton Dickinson, Sparks, MD, USA). A standard 
agar-proportion method with Middlebrook 7H10 media 
was used to conﬁ  rm resistance (16–18). If DST indicated 
isoniazid resistance, DNA sequencing of the catalase–
peroxidase G (katG) and enoyl reductase A (inhA) genes 
(19) was performed at the Public Health Research Institute 
Tuberculosis Center.
Contact Investigation
Contact investigations were conducted per BTBC 
guidelines (20). For contacts of infectious index patients, 
staff assessed hours of TB exposure during infectious 
periods of patients, deﬁ  ned as the 12-week period before 
the patient began appropriate TB treatment (20,21). 
Infectious periods were extended to date of symptom 
onset if TB symptoms started >12 weeks before treatment 
began. Contacts having documented latent TB infection 
or TB symptoms were referred for medical evaluation and 
treatment.
Cluster Investigation
An investigation of patients with the same M. 
tuberculosis strain was initiated to identify chains of 
transmission within the cluster and uncover epidemiologic 
links between TB patients. An epidemiologic link between 
2 patients indicated that patients were linked by person, 
place, or time. Deﬁ   nite epidemiologic links between 
patients required 1 of the following criteria: named another 
patient as a contact, had a common contact, reported 
being in the same location during a patient’s infectious 
period, or recognized each other’s names or photographs. 
Probable epidemiologic links indicated that patients were 
in the same location during the same date range regardless 
of the infectious period of either patient or that 1 patient 
recognized another’s name or photograph. Possible 
epidemiologic links occurred when patients lived or visited 
an area within 0.8 km (0.5 miles) of another or had a similar 
social environment. If >1 link was established between 2 
patients, the strongest link was counted.
Routine demographic and clinical data were obtained 
from the NYC TB registry and patient interviews. 
Additional data on homelessness and correctional history 
were obtained from NYC and New York State databases. 
Information regarding contacts and places of association 
(e.g., residences, worksites, and schools) of patients was 
analyzed to establish links between patients and to derive 
transmission hypotheses. To substantiate these hypotheses, 
we reinterviewed patients and their contacts by using a 
structured questionnaire. The questionnaire was updated 
with information obtained during patient interviews to 
ensure that hypotheses were reassessed throughout the 
investigation.
In October 2007, the NYC Department of Health and 
Mental Hygiene (DOHMH) Ofﬁ   ce of General Counsel 
approved use of names and photographs of patients 
and their contacts during interviews by BTBC. Cluster 
investigators administered informed consent forms. 
Consent forms indicated that names or photographs would 
be obtained and shown to persons being interviewed as part 
of the cluster investigation. If the patient denied voluntary 
permission but had an incarceration history, a public 
record booking photograph was used. To avoid disclosing 
conﬁ   dential medical information, ﬁ   ctitious names and 
unrelated photographs were included in the compilation 
of names and photographs. Investigators did not conﬁ  rm 
or deny a TB diagnosis of any person or how persons 
were related. During interviews, investigators asked if 
patients or contacts recognized any names or photographs. 
If recognition was indicated, the interviewer probed to 
understand how persons were linked.
Statistical Analysis
We compared categorical data by using Pearson χ2 
or Fisher exact tests, as appropriate. For continuous data, 
the Mann-Whitney test was used to compare medians. 
Statistical analyses were conducted by using SAS version 
9.1 (SAS Institute, Inc., Cary, NC, USA).
Places of association were geocoded through the 
NYC Department of City Planning’s Geosupport Desktop 
Edition Software 9.6.9. Geocoded locations were imported 
into ArcGIS 9.2 (ESRI, Redlands, CA, USA) and mapped. 
Locations not geocoded by street address were geocoded 
by street intersection or other features. The ArcGIS point 
distance geoprocessing tool was used to calculate Euclidean 
distances between places of association of patients. 
Data were obtained as part of an outbreak investigation. 
Therefore, NYC DOHMH and CDC deemed this activity 
nonhuman subjects research.
Results
During 2003–2009, we identiﬁ  ed 54 cases of TB as 
part of this cluster (Figure 1). Patient residence at TB 
diagnosis by NYC neighborhood is shown in Figure 2. 
Among 35 (65%) patients who lived in Upper Manhattan 
at diagnosis, median distance between the residence of any 
2 patients was 1.4 km (range 0.01 km–6.6 km). Median 
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distance between any 2 patients residing in the South Bronx 
(n = 10) at diagnosis was 2.9 km (range 0 km–5.8 km). 
Initially, the strain was susceptible to ﬁ  rst-line  anti-TB 
drugs. However, in 2006, isoniazid resistance emerged in a 
patient isolate at TB diagnosis. By 2009, 17 (31%) patients 
had isoniazid-resistant M. tuberculosis at diagnosis. All 
isoniazid-resistant isolates had the Ser315Thr mutation in 
the katG gene and no mutations in the inhA gene region 
sequenced.
TB Genotyping
Forty-seven (87%) of the 54 patients had isolates 
with a matching spoligotype, IS6110 RFLP pattern, and 
12-loci MIRU-VNTR result (Figure 3). Forty-eight (89%) 
isolates met the original cluster case deﬁ  nition. Six (11%) 
were identiﬁ  ed as cluster-associated patients on the basis 
of the expanded cluster case deﬁ  nition. As of December 
31, 2008, within the CDC National Tuberculosis 
Genotyping Service database of 32,581 patient isolates, 6 
with this cluster’s spoligotype and 12-loci MIRU-VNTR 
result were reported outside NYC (New York [n = 3], 
Delaware [n = 1], Georgia [n = 1], and Pennsylvania [n = 
1]) (22). Among the 3 patients who resided in New York 
State, 1 was diagnosed in NYC and is therefore counted 
in the cluster (Figure 1); no link to NYC was identiﬁ  ed for 
the other 2 patients.
Patient Characteristics
Patient median age was 41 years (range 10–77 years); 
74% were non-Hispanic black and 69% were male (Table). 
Among 37 patients with drug-susceptible M. tuberculosis, 
73% were male and 38% were foreign born. The 17 
patients with isoniazid-resistant M. tuberculosis were 
predominately US born (82%) and had a history of illegal 
drug use (59%) or incarceration (47%).
The shift of patient characteristics with time is shown 
in Figure 4. During 2003–2005, before isoniazid resistance 
emerged, 9 (64%) of 14 patients were US born and 4 
(44%) of the US-born patients reported illegal drug use. 
Three patients, of whom 2 attended the same mosque, had 
a country of origin in West Africa; none reported drug use. 
In 2006, the number of patients with drug-susceptible M. 
tuberculosis peaked at 11, of whom 8 (73%) were foreign-
born. All 4 patients from West Africa with drug-susceptible 
M. tuberculosis had a history of attending different 
mosques, and 2 had a history of illegal drug use. In 2007, 
when patients with isoniazid-resistant M. tuberculosis 
were more numerous than those with drug-susceptible M. 
tuberculosis, all 16 patients were US born; 8 (50%) were 
associated with illegal drug use. Of these 8 patients, 7 
(88%) had isoniazid-resistant M. tuberculosis.
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Figure 1. Cluster of 54 cases of tuberculosis (TB), by year of 
diagnosis, New York, New York, USA, 2003–2009. The 54 cases 
include 1 in a patient in the city of New York who was given a 
diagnosis of drug-susceptible Mycobacterium tuberculosis infection 
in 2007 that was counted by New York State.
Figure 2. Residences of patients (n = 54) at time of tuberculosis 
(TB) diagnosis, by neighborhood, New York, New York, USA, 
2003–2009. Forty-two neighborhoods were designated by the 
United Hospital Fund. Each neighborhood is deﬁ   ned by several 
adjoining ZIP codes (www.nyc.gov/html/doh/html/epi/mapgallery.
shtml).M. tuberculosis with Developing Drug Resistance 
Among the 22 persons who disclosed a history of illegal 
drug use, 19 (86%) indicated noninjection drug use. The 
mother of a child with isoniazid-resistant M. tuberculosis 
also reported using illegal drugs. Drugs mentioned by 
patients connected to illegal drug use included smoking or 
snorting cocaine (n = 15), smoking marijuana (n = 6), and 
using heroin (n = 3).
Contact Investigation
Among 48 patients eligible for contact investigation, 
1,226 contacts were identiﬁ   ed (median 9, range 0–153 
contacts/patient). Twelve investigations of TB exposures 
in congregate settings were conducted. None of the 
clustered patients named one another as contacts. Contact 
investigation identiﬁ   ed 1 clinically diagnosed TB case 
linked to a cluster-associated patient with drug-susceptible 
M. tuberculosis.
Cluster Investigation
All 2-patient combinations (n = 1,431) were analyzed 
for epidemiologic links. Routine cluster investigation 
identiﬁ   ed 3 deﬁ   nite epidemiologic links; only 1 of 
these links involved a patient with isoniazid-resistant 
M. tuberculosis. One deﬁ   nite epidemiologic link was 
based on a common contact between a patient with drug-
susceptible M. tuberculosis and a patient with isoniazid-
resistant M. tuberculosis. The other 2 links were based on 
patients living in the same apartment building during the 
infectious period of 1 of the patients. Cluster investigation 
methods identiﬁ   ed 3 probable epidemiologic links; all 
involved patients attending the same mosque during an 
overlapping date range. All 54 patients had a possible 
epidemiologic link to at least 1 other cluster patient; 98% 
of patients had multiple possible epidemiologic links. Of 
the possible epidemiologic links identiﬁ   ed, 81% were 
geographic and 29% involved illegal drug use. Other 
possible epidemiologic links were identiﬁ  ed on the basis 
of shared patient characteristics such as having a country 
of origin in West Africa, being infected with HIV, and 
history of mosque attendance, taxi driver occupation, 
incarceration, or homelessness.
During 2007–2009, patients were asked for permission 
to use names and photographs. Ten (59%) of the 17 patients 
with isoniazid-resistant M. tuberculosis, 1 (17%) of 6 
patients with drug-susceptible M. tuberculosis, and 7 (64%) 
of 11 contacts granted permission. Public-record booking 
photographs were used for 2 patients. Four additional 
probable epidemiologic links were established through 
name and photograph use; all were associated with illegal 
drug use. Patients did not indicate familiarity with ﬁ  ctitious 
names and unrelated photographs that were presented.
Discussion
Despite using substantial resources within BTBC and 
beyond, we did not clearly identify chains of transmission 
in this outbreak. Only 3 deﬁ  nite epidemiologic links were 
identiﬁ  ed between patients, and only 1 was associated with 
the rapidly emerging or spreading isoniazid-resistant strain. 
The strongest link of this cluster is geographic; patients 
primarily spent time in the same neighborhoods. Although 
matching genotype does not always signify recent 
transmission, geospatial concentration and epidemiologic 
data indicate ongoing and recent transmission of this rare 
genotype in NYC. Contact investigation results showed 
evidence of possible transmission. However, no conﬁ  rmed 
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Figure 3. IS6110 restriction fragment length polymorphism patterns 
for tuberculosis patients, New York, New York, USA, 2003–2009. 
Left lane, molecular mass ladder; lane A, n = 48; lane B, n = 1; lane 
C, n = 1; lane D, n = 4. Spoligotype results (octal code designation) 
were 777777774020771 for 54 patients. Twelve-loci mycobacterial 
interspersed repetitive-unit variable-number tandem repeat results 
were 225313153321 for 53 patients and 2253131–3321 for 1 
patient; the dash indicates that there was no peak at this locus 
for this 1 patient, and the patient with this isolate met the original 
cluster case deﬁ  nition. RESEARCH
secondary TB cases were identiﬁ   ed among >1,200 
identiﬁ   ed contacts, further demonstrating limitations of 
name-based contact investigation.
This outbreak was only identiﬁ  ed through genotyping. 
PCR-based methods (spoligotyping and 12-loci 
MIRU-VNTR analysis) better deﬁ   ned this TB cluster. 
Supplementing contact investigation with laboratory tools 
to examine strain relatedness (e.g., real-time genotyping 
and DST) can help TB control program staff identify and 
investigate outbreaks. Although all patient specimens had a 
matching genotype, DST results showed 2 phenotypes, and 
therefore >2 distinct transmission chains within the cluster. 
Identifying separate transmission chains enabled cluster 
investigators to develop and test hypotheses speciﬁ  c  to 
each chain of transmission. Common characteristics within 
each transmission chain implied discrete social networks, 
but these networks could not be conﬁ  rmed by using routine 
cluster investigation methods.
Emergence of isoniazid resistance in this cluster 
cannot be clearly explained. None of the patients with 
drug-susceptible  M. tuberculosis showed failure of 
treatment. Presumably, 1 person, identiﬁ  ed by investigators 
as a shared contact between a patient with drug-susceptible 
M. tuberculosis and a patient with isoniazid-resistant M. 
tuberculosis, had a history of taking medications for TB and 
showed development of isoniazid-resistant M. tuberculosis 
that had not been reported to BTBC. This person died; 
therefore, cluster investigators were unable to conﬁ  rm this 
hypothesis despite medical record review and pharmacy 
surveillance.
This investigation was limited by patients’ 
unwillingness to report their contacts, possibly because of 
fear of disclosing immigration status (not asked by BTBC 
staff), illegal drug use, or involvement in other illicit 
activities. Other possible explanations include forgetting 
or not knowing their contacts by name (2,23). Certain 
patients used aliases (not tracked in the NYC TB registry) 
and claimed to only know their contacts by ﬁ  rst names 
or aliases. Pervasiveness of aliases within patient social 
networks stymied contact investigation efforts and made 
establishing epidemiologic links between patients difﬁ  cult.
High prevalence of illegal drug use within the cluster 
led investigators to explore how speciﬁ  c drug-use practices 
contribute to TB transmission. Studies reported that such 
speciﬁ   c drug-use practices as shotgunning (inhaling 
smoke from rock cocaine or marijuana and blowing the 
smoke directly into the mouth of another) and hotboxing 
(smoking drugs in a small, enclosed space to maximize 
narcotic effect through ﬁ  rst-hand and second-hand smoke) 
were associated with TB transmission (24,25). Although 
these practices were not speciﬁ  cally mentioned by patients 
or their contacts, speciﬁ  c questions were not asked until 
later in the investigation. After consulting with substance-
use experts, BTBC revised their cluster-investigation 
questionnaire and provided investigators with additional 
training on patient-interview procedures and drug-use 
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Table. Characteristics of 54 TB patients, by drug susceptibility test results, New York, New York, USA, 2003–2009* 
Characteristic All patients
Type of Mycobacterium tuberculosis
p value
Drug-susceptible,
n = 37
Isoniazid-resistant, 
n = 17
Median age at TB diagnosis, y (range) 41 (10–77) 42 (12–77) 39 (10–52) 0.12
Male sex 37 (69) 27 (73) 10 (59) 0.30
Race/ethnicity
 Asian 1 (2) 1 (3) 0 1.00†
 Hispanic 13 (24) 8 (22) 5 (29) 0.73†
 Black,  non-Hispanic 40 (74) 28 (76) 12 (71) 0.74†
Country of origin
 United  States 36 (67) 22 (59) 14 (82) 0.10
 Foreign 17 (31) 14 (38) 3 (18) 0.14
 Unknown 1 (2) 1 (3) 0 1.00†
History of illegal drug use‡ 22 (41) 12 (32) 10 (59) 0.07
History of homelessness 13 (24) 8 (22) 5 (29) 0.73†
History of incarceration 12 (22) 4 (11) 8 (47) <0.01†
Pulmonary site of TB§ 48 (89) 32 (87) 16 (94) 0.65†
Cavitary (among cases with pulmonary site of disease) 12 (25) 7 (22) 5 (31) 0.50†
Acid-fast bacilli smear positive for respiratory specimen 38 (70) 24 (65) 14 (82) 0.19
HIV status
 Positive 14 (26) 9 (24) 5 (29) 0.74†
 Negative 37 (69) 26 (70) 11 (65) 0.68
 Unknown 3 (6) 2 (5) 1 (6) 1.00†
*Values are no. (%) unless otherwise indicated. TB, tuberculosis. 
†By Fisher exact test. 
‡Use of injection (e.g., heroin) or noninjection (e.g., marijuana or cocaine) drugs indicated on any patient record. 
§Includes patients with only pulmonary sites of disease and patients with pulmonary and extrapulmonary sites of disease. M. tuberculosis with Developing Drug Resistance 
subculture. Understanding drug-use behavior helps TB 
control personnel elicit sensitive transmission information. 
BTBC also modiﬁ   ed how substance-use information is 
collected and recorded in the TB registry.
Transmission through casual contact and increased 
virulence are possible explanations for extensive 
transmission of this strain and lack of recognition among 
patients. Although TB transmission from casual contact 
is considered rare, it has been documented (26–30). If 
this strain, like other outbreak strains (29), was highly 
virulent, extensive transmission among patients who 
did not recognize each other would have been possible. 
Moreover, geographic proximity of patients to one another 
might have increased opportunities for TB exposure 
and supported transmission through casual contact. In 
addition, positive results for acid-fast bacilli in smears of 
respiratory specimens among cluster-associated patients 
were substantial (70% overall, 93% among cocaine users) 
and considerably greater than recent past NYC TB patients 
(range 42%–46% during 2003–2008) (NYC DOHMH, 
unpub. data), thus increasing likelihood of transmission. 
Investigation  ﬁ   ndings were consistent with those of a 
London study that reported that pulmonary TB patients 
who used cocaine were more likely to be sputum smear 
positive at diagnosis (31), perhaps related to delays in 
seeking medical care.
Photograph and name use yielded the strongest 
epidemiologic links between patients with isoniazid-
resistant  M. tuberculosis. It was the only method that 
conﬁ   rmed patient recognition within the cluster. All 
epidemiologic links established through photograph 
recognition were related to illegal drug activity. Other 
outbreak investigations have highlighted unwillingness of 
patients to share social contacts when these contacts are 
connected to illegal activities (4,5,13).
Insights gained from using name and photograph 
data in an ongoing investigation will beneﬁ  t TB control 
programs. This method would have been more successful 
if used earlier in the investigation. TB control personnel 
contemplating adopting this strategy should obtain legal 
guidance before an outbreak occurs because privacy laws 
vary from one locality to another.
This outbreak investigation highlights an array 
of challenges for US-based TB control programs. 
Understanding and preventing TB transmission among 
hard-to-reach populations requires considerable resources. 
Conventional contact investigation can be inadequate for 
identifying and curtailing TB transmission among difﬁ  cult-
to-reach- populations. New methods, including using name 
and photograph data, are needed for TB elimination.
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Figure 4. Common characteristics among 
54 patients infected with Mycobacterium 
tuberculosis, by year of tuberculosis 
diagnosis and drug susceptibility testing 
results, New York, New York, USA, 2003–
2009.RESEARCH
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